{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:44:48Z","timestamp":1791521088308,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13555-021-00564-2","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:07:21Z","timestamp":1623308841000},"page":"1373-1384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase\u00a03 Clinical Trials of Secukinumab"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01365455","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01358578","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01555125","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katherine","family":"Houghton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braulio","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","unstructured":"Langley RGB, Krueger GG, Griffiths CEC. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl II):ii18\u201323. https:\/\/doi.org\/10.1136\/ard.2004.033217.","DOI":"10.1136\/ard.2004.033217"},{"issue":"3","key":"564_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2013.11.013.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"564_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e219. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"564_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.023.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"564_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"564_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2013.12.018.","journal-title":"J Am Acad Dermatol"},{"key":"564_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"564_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"564_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2018.1401468","volume":"14","author":"J Frieder","year":"2018","unstructured":"Frieder J, Kivelevitch D, Fiore CT, Saad S, Menter A. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Rev Clin Immunol. 2018;14(1):1\u201319. https:\/\/doi.org\/10.1080\/1744666X.2018.1401468.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"564_CR10","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/ajd.12353","volume":"57","author":"C Chaptini","year":"2016","unstructured":"Chaptini C, Quinn S, Marshman G. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study. Australas J Dermatol. 2016;57(3):e72\u20135. https:\/\/doi.org\/10.1111\/ajd.12353.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"564_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jdv.14007","volume":"31","author":"L Puig","year":"2017","unstructured":"Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213\u201320. https:\/\/doi.org\/10.1111\/jdv.14007.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"564_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/bjd.16366","volume":"178","author":"DE Stull","year":"2018","unstructured":"Stull DE, Griffiths CEM, Gilloteau I, et al. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018;178(6):1297\u2013307. https:\/\/doi.org\/10.1111\/bjd.16366.","journal-title":"Br J Dermatol"},{"issue":"4","key":"564_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"issue":"2","key":"564_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393. https:\/\/doi.org\/10.1111\/bjd.13348.","journal-title":"Br J Dermatol"},{"issue":"6","key":"564_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390. https:\/\/doi.org\/10.1111\/jdv.12751.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"564_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"564_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13555-017-0211-4","volume":"8","author":"D Pariser","year":"2018","unstructured":"Pariser D, Frankel E, Schlessinger J, et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis in the North American subgroup of patients: pooled analysis of four phase\u00a03 studies. Dermatol Ther (Heidelb). 2018;8(1):17\u201332. https:\/\/doi.org\/10.1007\/s13555-017-0211-4.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"564_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","volume":"31","author":"A Pinter","year":"2020","unstructured":"Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769\u201375. https:\/\/doi.org\/10.1080\/09546634.2019.1626973.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"564_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/1346-8138.12538","volume":"41","author":"Y Umezawa","year":"2014","unstructured":"Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol. 2014;41(8):690\u20136. https:\/\/doi.org\/10.1111\/1346-8138.12538.","journal-title":"J Dermatol"},{"issue":"5","key":"564_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/1346-8138.13681","volume":"44","author":"YJ Hwang","year":"2017","unstructured":"Hwang YJ, Youn SW, Kim BR, et al. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis. J Dermatol. 2017;44(5):560\u20136. https:\/\/doi.org\/10.1111\/1346-8138.13681.","journal-title":"J Dermatol"},{"issue":"1","key":"564_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/jid.2013.326","volume":"134","author":"E Edson-Heredia","year":"2014","unstructured":"Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18\u201323. https:\/\/doi.org\/10.1038\/jid.2013.326.","journal-title":"J Invest Dermatol"},{"key":"564_CR22","unstructured":"The bmj. 11. Correlation and regression, 2019. https:\/\/www.bmj.com\/about-bmj\/resources-readers\/publications\/statistics-square-one\/11-correlation-and-regression. Accessed April 9, 2021."},{"key":"564_CR23","doi-asserted-by":"publisher","unstructured":"Lanna C, Galluzzi C, Zangrilli A, Bavetta M, Bianchi L, Campione E. Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. J Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2020.1770175.","DOI":"10.1080\/09546634.2020.1770175"},{"issue":"2","key":"564_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jdv.16632","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35(2):431\u201340. https:\/\/doi.org\/10.1111\/jdv.16632.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"564_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333\u20137. https:\/\/doi.org\/10.1111\/jdv.12106.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"564_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/09546634.2018.1466023","volume":"29","author":"R Romiti","year":"2018","unstructured":"Romiti R, Fabr\u00edcio LHZ, Souza CDS, et al. Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). J Dermatolog Treat. 2018;29(8):775\u201385. https:\/\/doi.org\/10.1080\/09546634.2018.1466023.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"564_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.e77. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"564_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"564_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9(1):5\u201318. https:\/\/doi.org\/10.1007\/s13555-018-0279-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"564_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/09546634.2015.1093589","volume":"27","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Bushnell DM, Klekotka PA, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016;27(3):224\u20137. https:\/\/doi.org\/10.3109\/09546634.2015.1093589.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"564_CR31","first-page":"173","volume":"95","author":"E Edson-Heredia","year":"2015","unstructured":"Edson-Heredia E, Zhu B, Guo J, Maeda-Chubachi T, Lebwohl M. Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. Cutis. 2015;95(3):173\u20138.","journal-title":"Cutis"},{"issue":"12","key":"564_CR32","doi-asserted-by":"publisher","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20132011. PLoS One. 2012;7(12):e52935.","journal-title":"PLoS One"},{"issue":"9","key":"564_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","volume":"104","author":"E Daud\u00e9n","year":"2013","unstructured":"Daud\u00e9n E, Pujol RM, S\u00e1nchez-Carazo JL, et al. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study. Actas Dermosifiliogr. 2013;104(9):807\u201314. https:\/\/doi.org\/10.1016\/j.ad.2013.03.005.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"564_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00403-019-01906-z","volume":"311","author":"A Duvetorp","year":"2019","unstructured":"Duvetorp A, \u00d8stergaard M, Skov L, et al. Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Arch Dermatol Res. 2019;311(5):351\u201360. https:\/\/doi.org\/10.1007\/s00403-019-01906-z.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"564_CR35","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s11136-016-1321-7","volume":"25","author":"M Obradors","year":"2016","unstructured":"Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25(11):2739\u201354. https:\/\/doi.org\/10.1007\/s11136-016-1321-7.","journal-title":"Qual Life Res"},{"issue":"3","key":"564_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2011","unstructured":"Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatol (Oxford). 2011;51(3):571\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/ker365.","journal-title":"Rheumatol (Oxford)"},{"issue":"9","key":"564_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215003.","journal-title":"Ann Rheum Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00564-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:41:34Z","timestamp":1628613694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00564-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"20 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}